Who are Lipo-PGE1's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cytotec, Misoprostol 400 Microgram Oral Tablet, low dose peroral misoprostol, preoperative vaginal misoprostol, Alprostadil ﹠control, Cytotec (reference drug).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lipo-pge1.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Lipo-PGE1 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lipo-PGE1 (Lipo-PGE1) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostaglandin E1 analog. Area: Cardiovascular.

marketed Prostaglandin E1 analog Prostaglandin E receptor (EP receptors) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Lipo-PGE1 (Lipo-PGE1) — West China Hospital. Lipo-PGE1 is a lipid-formulated prostaglandin E1 that promotes vasodilation and improves blood flow by activating prostanoid receptors on vascular smooth muscle and endothelial cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lipo-PGE1 TARGET	Lipo-PGE1	West China Hospital	marketed	Prostaglandin E1 analog	Prostaglandin E receptor (EP receptors)
Cytotec	misoprostol	Generic (originally Searle/Pfizer)	marketed	Prostaglandin E1 analog	Prostaglandin E2 receptor EP2 subtype, Prostaglandin E2 receptor EP3 subtype, Prostaglandin E2 receptor EP4 subtype	1988-12-27
Misoprostol 400 Microgram Oral Tablet	Misoprostol 400 Microgram Oral Tablet	Assuta Ashdod Hospital	marketed	Prostaglandin E1 analogue	Prostaglandin E receptor (EP receptor)
low dose peroral misoprostol	low dose peroral misoprostol	University Medical Centre Ljubljana	marketed	Prostaglandin E1 analogue	Prostaglandin E receptor (EP receptor)
preoperative vaginal misoprostol	preoperative vaginal misoprostol	Ain Shams Maternity Hospital	marketed	Prostaglandin E1 analogue	Prostaglandin E receptor (EP receptor)
Alprostadil ﹠control	Alprostadil ﹠control	Shanghai 10th People's Hospital	marketed	Prostaglandin E1 analog	Prostanoid receptors (EP receptors)
Cytotec (reference drug)	Cytotec (reference drug)	Dong-A ST Co., Ltd.	marketed	Prostaglandin E1 analog	Prostaglandin E receptor (EP receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostaglandin E1 analog class)

Dong-A ST Co., Ltd. · 1 drug in this class
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia · 1 drug in this class
Generic (originally Searle/Pfizer) · 1 drug in this class
Shanghai 10th People's Hospital · 1 drug in this class
West China Hospital · 1 drug in this class
Wolfson Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lipo-PGE1 — Competitive Intelligence Brief. https://druglandscape.com/ci/lipo-pge1. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing